Highlights

  • Microba Life Sciences Limited (ASX: MAP) has appointed an Interim Chief Executive Officer while founder Dr Luke Reid is on medical leave.
  • Geoffrey Cockerill, a veteran executive with roles at Diageo, Lion, Subway Systems and Vitura Health, steps into the role from 29 September 2026.
  • The six-month contractor engagement carries a fixed daily fee, with no Equity or performance-based incentives attached.
  • The appointment reporting line and termination terms outline how the company plans to manage Leadership continuity during the transition.

Microba Life Sciences Limited (ASX:MAP) has announced a leadership change at the top of the organisation, confirming that founding Chief Executive Officer Dr Luke Reid is currently on medical leave. In response, the Board has appointed Geoffrey Cockerill as Interim Chief Executive Officer, with the appointment taking effect from 29 September 2026. The company has kept its statement on Dr Reid's absence brief and respectful of his privacy, noting only that he is on medical leave without providing further detail on the nature or expected duration of his absence.

The appointment of an interim chief executive is a standard governance mechanism used by listed companies to maintain continuity of leadership when a sitting CEO is temporarily unavailable. For Microba, a company operating in the life sciences and microbiome diagnostics space, ensuring stable executive oversight during this period allows ongoing operations, regulatory obligations and stakeholder communications to continue without disruption while Dr Reid focuses on his recovery.

Background and Experience of the Interim CEO

Geoffrey Cockerill brings more than 30 years of executive leadership experience gathered across large organisations both in Australia and internationally. His career has spanned consumer-facing and health-adjacent businesses, including senior roles at Diageo Australia and Lion, two well-known names in the beverages sector, as well as at Subway Systems, where he served as Regional Director for Australia, New Zealand and South-East Asia. This breadth of experience across multi-market consumer businesses is often viewed as valuable preparation for the kind of cross-functional oversight an interim CEO role demands.

More recently, Mr Cockerill served as Chief Executive Officer of ASX-listed Vitura Health Limited, giving him direct prior experience operating at the helm of a publicly listed healthcare-related company, including familiarity with ASX disclosure obligations, governance expectations and board reporting. Before that, he held the CEO role at ATP Science. According to the company's announcement, his experience covers "organisational transformation, operational improvement, cost and efficiency programs and commercial growth initiatives," a skill set that is commonly sought when a company needs a steady hand to manage the Business through a transitional period.

On the academic and professional development side, Mr Cockerill holds a Bachelor of Commerce with a major in Marketing and Human Resources, and has completed the Australian Institute of Company Directors program, a widely recognised director education course in Australia that covers corporate governance, board duties and director responsibilities under the Corporations Act.

Terms of the Interim Appointment

The terms of Mr Cockerill's engagement have been structured in a manner typical of interim executive appointments at ASX-listed companies. He will act as Interim Chief Executive Officer reporting directly to the Board Chair, and importantly, the role is not a director position, meaning he will not sit on the Microba Board itself. He has been engaged as an independent contractor rather than as a direct employee, for an initial term of six months, which may be extended by agreement between Mr Cockerill and the company if circumstances require.

Compensation for the role has been set at a daily fee of $2,100, excluding GST but inclusive of superannuation, calculated on the basis of a five-day working week. Notably, the arrangement does not include any incentive payments, equity awards or performance-based fees, distinguishing it from the more complex long-term remuneration packages typically used for permanent chief executive appointments. This straightforward, fixed daily-fee structure is consistent with market practice for interim leadership roles, where the emphasis is on providing continuity of management rather than aligning pay with longer-term share price or performance outcomes.

The engagement can be terminated by either party with four weeks' written notice, while the company retains the right to terminate immediately for cause, a standard protection built into most executive contracts to allow swift action in the event of serious misconduct or breach.

Why Companies Use Interim CEO Arrangements

Interim CEO appointments of this kind serve an important governance function for listed companies. When a sitting chief executive is temporarily unavailable, a board's primary responsibility is to ensure that decision-making authority, external communications and day-to-day management responsibilities continue without a leadership vacuum. Appointing an experienced outside executive on a fixed-term, clearly bounded contract, rather than promoting from within on an ad hoc basis, allows a company to bring in someone who already has broad operating experience while avoiding long-term commitments that might later need to be unwound.

For shareholders and other Stakeholders monitoring Microba Life Sciences, the announcement provides clarity on three fronts: who is currently responsible for running the company, on what basis that person has been engaged, and how long the arrangement is expected to last before it is reviewed or extended. The six-month term, with the option to extend by agreement, gives both the company and Mr Cockerill a defined period within which to assess whether Dr Reid is able to return to his substantive role, or whether the Board needs to consider longer-term leadership arrangements.

The company's disclosure keeps the focus firmly on governance continuity rather than on the specifics of Dr Reid's health, consistent with the respectful approach typically taken by listed companies when disclosing a leader's medical leave. No further details regarding Dr Reid's condition or expected return date were provided in the announcement.

Key Insights

Microba Life Sciences Limited's appointment of Geoffrey Cockerill as Interim Chief Executive Officer reflects a standard governance response to a temporary leadership gap, structured as a fixed-term, non-director contractor role reporting to the Board Chair. Mr Cockerill's background across consumer and healthcare-adjacent businesses, together with prior experience leading an ASX-listed company, positions him to maintain operational continuity during Dr Luke Reid's medical leave. The six-month term, fixed daily fee, and absence of equity or performance incentives are consistent with how interim leadership arrangements are typically structured across the ASX-listed market, giving the Board a defined window to reassess leadership needs as circumstances evolve.